TY - JOUR
T1 - The role of adjuvant monoclonal antibody therapy for breast cancer
T2 - rationale and new studies.
AU - Perez, E. A.
N1 - Funding Information:
This work is partially supported by grants from the Breast Cancer Research Foundation, New York, and by NCI grant U10CA25224-21.
PY - 2001/11
Y1 - 2001/11
N2 - HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive resected breast cancer is based on several factors. These include 1) the relative and absolute poor prognosis of patients with node-positive, HER2-positive breast cancer; 2) the emerging data of potential importance concerning anthracyclines as a component of adjuvant therapy for patients with HER2-positive breast cancer; 3) the role of taxanes in the management of patients with HER2-positive metastatic breast cancer; and 4) the feasibility and efficacy of molecularly targeted anti-HER2 monoclonal antibody treatment alone or in combination with chemotherapy for patients with advanced breast cancer.
AB - HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive resected breast cancer is based on several factors. These include 1) the relative and absolute poor prognosis of patients with node-positive, HER2-positive breast cancer; 2) the emerging data of potential importance concerning anthracyclines as a component of adjuvant therapy for patients with HER2-positive breast cancer; 3) the role of taxanes in the management of patients with HER2-positive metastatic breast cancer; and 4) the feasibility and efficacy of molecularly targeted anti-HER2 monoclonal antibody treatment alone or in combination with chemotherapy for patients with advanced breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0035514398&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035514398&partnerID=8YFLogxK
U2 - 10.1007/s11912-001-0073-9
DO - 10.1007/s11912-001-0073-9
M3 - Review article
C2 - 11595120
AN - SCOPUS:0035514398
SN - 1523-3790
VL - 3
SP - 516
EP - 522
JO - Current oncology reports
JF - Current oncology reports
IS - 6
ER -